^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:cabazitaxel (Microtubule inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

    Excerpt:
    ...- Histologically confirmed 1) HER2-negative invasive breast carcinoma or 2) NSCLC...
    Trial ID:
    NCT01913067
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

    Excerpt:
    ...- Diagnosis of HER-2 negative (HER-2 ULN (the same limits also refer to patients with liver metastases)...
    Trial ID:
    NCT01693549
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Study assessing if a chemotherapy drug called Cabazitaxel is effective in Patients with certain type of breast cancer (HER2 negative) that has spread to brain that is un treatable.

    Excerpt:
    ...• First or second line metastatic HER2 negative* breast cancer• Oligometastatic brain disease that is unsuitable for surgical resection and/or stereotactic radiosurgery • Age ≥18 years• ECOG performance status 0-2 • Diagnosis of metastatic HER2-negative breast cancer• At least one measurable target lesion (RECIST 1.0) in the brain (unsuitable for resection) identified by CT scan or MRI within 21 days of registration. ...
    Trial ID:
    2012-000542-35
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Phase II study of cabazitaxel as second-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.

    Published date:
    05/16/2018
    Excerpt:
    ...phase II trial was to evaluate the activity and safety of cabazitaxel as 2nd-line treatment, given on day 1 of a 21-day cycle, in patients with HER-2 negative metastatic breast cancer...In the 77 patients with evaluable treatment response, the ORR was 24.7% (1 complete and 18 partial responses). The disease-control rate was 58.4%, while the median DOR was 5.6 months (range 0.7-51.3). Within a median follow-up of 32.2 months, the median PFS was 3.7 months (95% CI 2.23-4.36), whereas the median OS was 15.2 months (95% CI 11.21-21.54).
    DOI:
    10.1200/JCO.2018.36.15_suppl.1089
    Trial ID:
    NCT01693549